We recently published a list of Top 10 Stocks to Buy According to Akre Capital Management. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other top stocks to buy according to Akre Capital Management.

Akre Capital Management follows a disciplined investment philosophy centered around identifying exceptional businesses managed by honest and capable leaders who reinvest free cash flow wisely. This approach, referred to as the “three-legged stool,” emphasizes three key factors: extraordinary businesses, strong management teams, and effective reinvestment strategies. The firm’s primary objective is to compound investor capital at above-average rates while maintaining a lower level of risk compared to industry norms. Led by founder Chuck Akre until 2020, the firm has consistently adhered to this philosophy, delivering strong results over the years.

The foundation of Akre Capital’s investment strategy is built on the principle that long-term returns closely correlate with the return on an owner’s capital, assuming stable valuations and no distributions. Historically, the average return on U.S. equities has been around 9% to 10%, aligning with book value growth per share. Akre Capital seeks to outperform this benchmark by selecting businesses with superior return profiles, believing that these “compounding machines” are the best way to achieve sustainable wealth accumulation. The firm places great emphasis on patience and discipline, resisting short-term market fluctuations in favor of long-term growth.

Unlike many asset managers, Akre Capital does not rely on setting specific sell targets when acquiring shares. Instead, it evaluates potential investments with the intent of holding them indefinitely, selling only when one of the core aspects of the “three-legged stool” is compromised. This long-term approach distinguishes the firm from Wall Street’s frequent short-term focus on quarterly earnings surprises. Rather than reacting to minor earnings fluctuations, Akre Capital remains committed to businesses with solid economic fundamentals, viewing temporary price declines as opportunities to acquire high-quality companies at attractive valuations.

Another key differentiator of Akre Capital is its ability to capitalize on market inefficiencies. The firm takes advantage of Wall Street’s obsession with short-term earnings reports, often using quarterly “misses” as opportunities to invest in undervalued companies with strong long-term potential. With a focus on growth over five- and ten-year periods, Akre Capital prioritizes economic value per share rather than short-term stock price movements. This steadfast commitment to its investment philosophy has allowed the firm to consistently achieve its goal of compounding capital while mitigating risk.

Charles T. “Chuck” Akre, Jr. is a seasoned asset manager with over five decades of experience overseeing private funds, mutual funds, and separately managed accounts. He founded Akre Capital Management in 1989 after spending 21 years at Johnston, Lemon & Co., a NYSE member firm, where he gained expertise in research, asset management, and branch operations. During his time there, he developed a deep understanding of securities and investment strategies, which laid the foundation for his own firm’s approach.

From 1993 to 2000, Akre Capital Management operated under the umbrella of Friedman, Billings, Ramsey & Co. in Washington, D.C., providing Chuck with additional resources to refine and expand his investment philosophy. However, in 2000, he chose to take the firm private again, emphasizing independence and a long-term investment approach. He relocated Akre Capital to Middleburg, Virginia, a rural setting that reflected his preference for a focused and patient investment process, free from the distractions of Wall Street’s short-term mentality.

At Akre Capital, Chuck Akre’s leadership has shaped the firm’s long-term success, ensuring consistent capital growth for investors. Over the years, he has earned a reputation for his disciplined and insightful approach to asset management. Today, Akre continues to contribute his expertise as Chairman of Akre Capital Management. He works alongside John Neff, the portfolio manager of the Akre Focus Fund, ensuring that the firm’s investment principles remain intact. With decades of experience and a commitment to compounding capital at superior rates, Chuck Akre’s influence in the investment world remains significant.

As of its most recent filing for the fourth quarter of 2024, Akre Capital Management manages approximately $11.56 billion in 13F securities. The firm maintains a highly concentrated portfolio, with its top ten holdings accounting for 94.82% of total assets. This focused investment approach reflects Akre Capital’s commitment to selecting a small group of high-quality businesses with strong growth potential and disciplined management.

Our Methodology

The stocks discussed below were picked from Akre Capital Management’s Q4 2024 13F filings. They are compiled in the ascending order of the hedge fund’s stake in them as of December 31, 2024. To assist readers with more context, we have included the hedge fund sentiment regarding each stock using data from 1009 hedge funds tracked by Insider Monkey in the fourth quarter of 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Danaher Corporation (NYSE:DHR)

Number of Hedge Fund Holders as of Q4: 101

Akre Capital Management’s Equity Stake: $407.54 Million 

Danaher Corporation (NYSE:DHR) is a global conglomerate specializing in medical, industrial, and commercial products and services. Founded in 1984 by Steven and Mitchell Rales, the company is headquartered in Washington, D.C., and operates through three primary divisions: biotechnology, diagnostics, and life sciences. With a strong emphasis on scientific and technological innovation, Danaher aims to address critical health challenges and improve quality of life worldwide. Originally established as DMG, Inc. in 1969, the company underwent several transformations before adopting its current name, inspired by a Montana creek. Danaher Corporation (NYSE:DHR) was also among the first North American companies to implement Kaizen principles, focusing on continuous improvement and operational efficiency.

As of the fourth quarter of 2024, Akre Capital Management held 1.78 million shares of Danaher Corporation (NYSE:DHR), valued at approximately $407 million, making up 3.52% of Charles Akre’s investment portfolio. Hedge fund interest in Danaher also increased, with 101 out of 1,009 funds tracked by Insider Monkey holding positions worth nearly $7.07 billion by the end of the fourth quarter, up from 98 funds in the previous quarter. This growing investor confidence highlights Danaher’s strong market position and long-term potential.

On January 28, 2025, Danaher Corporation (NYSE:DHR) reported its fourth-quarter earnings, posting a net revenue of $6.54 billion, reflecting a 2% increase year over year. However, the company’s earnings per share (EPS) came in at $2.14, falling short of analyst expectations by $0.02. Analysts maintain a stable outlook for the stock, projecting 2025 revenues of $24.1 billion and a 5% increase in earnings per share (EPS) to $5.74, aligning closely with prior estimates. Despite the slight earnings miss, Danaher’s steady revenue growth and commitment to innovation reinforce its position as a key player in the healthcare and life sciences industries, making it one of the top stocks to buy according to Akre Capital Management.

Mar Vista U.S. Quality Strategy stated the following regarding Danaher Corporation (NYSE:DHR) in its Q4 2024 investor letter:

“Healthcare stocks in general, and Life Science tool businesses more specifically, ended 2024 on a downbeat as investor sentiment is still cautious on the market’s post-Covid recovery. Hopes for an above average industry growth rebound in 2025 were muted by managements’ more cautious guidance. Investor concerns over the Trump administration’s healthcare leadership and policies further dampened optimism for a strong 2025. Tariff impacts, NIH funding and Biotech/pharma spending top the list of investor concerns. We believe Mettler-Toledo’s and Danaher Corporation’s (NYSE:DHR) secular growth opportunities stay intact. Both businesses compete in key, defensible segments of the industry’s value chain and have strong pricing power and margin expansion opportunities. Long-term secular drivers for scientific research and commercialization of biologic therapeutics and molecular diagnostic should drive above-average growth for both businesses.”

Overall, DHR ranks 10th on our list of top stocks to buy according to Akre Capital Management. While we acknowledge the potential for DHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DHR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.